infigratinib 0.25 mg/kg/day

DRUG2 trials

Sponsors

QED Therapeutics, a BridgeBio company

Conditions

AchondroplasiaHypochondroplasia

Phase 2

An Interventional Study of Infigratinib in Children With Hypochondroplasia

Enrolling by invitationNCT06873035

QED Therapeutics, a BridgeBio companyHypochondroplasia

Start: 2025-04-22End: 2027-01-01Target: 24Updated: 2026-07-16

Phase 3

A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia

CompletedNCT06164951

QED Therapeutics, a BridgeBio companyAchondroplasia

Start: 2023-11-10End: 2025-12-18Updated: 2026-03-17